ASTRAZENECA PLC beat first-quarter profit estimates on Wednesday midday, reporting core EPS of $2.58 on $15.29 billion in revenue. The results surpassed analyst expectations of $2.54 per share and $14.9 billion in sales, driven by 16% growth in oncology. Investors are weighing this operational strength against warnings that United States pricing policies could delay global drug launches.
AstraZeneca Beats Q1 Profit Estimates and Issues Warning
AstraZeneca beat first-quarter profit estimates on strong oncology sales. CEO Pascal Soriot warned that U.S. pricing policies could impact global drug launches.
Xurve View
洞察:
Xurve View











